The following video is part of our "Motley Fool Conversations" series, in which health-care editor/analyst David Williamson and consumer goods editor and analyst Austin Smith discuss topics across the investing world.
In today's edition, David and Austin discuss Cell Therapeutics' recent pipeline-bolstering purchase. Normally investors applaud such deals; however, Cell Therapeutics has seen a backlash from the investment community. David and Austin catch viewers up on the controversy and discuss what this deal means for Cell Therapeutics, its shareholders, and its potential competitors.
Health-care investors are always looking for the next big breakthrough. Motley Fool co-founder David Gardner recently identified a small-cap health-care company that he believes is poised for monster returns. To uncover this top pick today, enjoy the special free report: "Discover the Next Rule-Breaking Multibagger." Don't miss out on this limited-time offer and your opportunity to discover this game-changing company before the market does. Click here to access your report -- it's totally free.Austin Smith has no positions in the stocks mentioned above. David Williamson has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Why CTI BioPharma Corp. Stock Popped Today
The blood-cancer-focused biotech isn't out of the woods yet, but it looks like it will finally be allowed to continue an important clinical trial.
Why CTI BioPharma Corp. Came Crashing Down Today
Another day, another stock offering for CTI BioPharma .
This Biotech Stock Could Face a Cash Crunch in 2016
A shrinking cash balance and steady operating losses could spell trouble for these biotech stocks in 2016.